NASDAQ Meso daily flow charts, page-131

Careful what you ask for re the daily runs@Wilba32

Great post re Motley interview, thankyou.

Two things stood out.

First, here was another patient ( woo hoo) who had no cover ( boo hoo) but we provided treatment at our cost ( hooray).

Second, the meeting with the FDA has not been held as yet.


Maybe a third item- it was the way Si described " And we will continue to study and do one more study to validate and confirm the initial
findings of an 80% reduction in heart attacks"

Now we know that we are hopeful for an AA with a confirmatory trial. But , to me, this was phrased in a way that a study will take place regardless and the primary end point will be reduction in heart attacks.

My non medical training has kicked in- don't use reduction in strokes nor death as endpoints as these can be caused by other factors.

Revascor is treating heart function- reduce heart attacks, get approved.

I see a Big Daddy Pharma perched on Silviu's shoulder here. The meeting with the FDA is for clarity on Revascor - potency assays , CMC items- similar to the issues they had to navigate with Ryoncil.


I was pinning my hopes on an AA, now I think a global heart partnership is waiting on the outcome of that meeting, whether there is an opportunity to file for a AA or not.


Beware my massive confirmation bias- purchase at your own peril- please, as my wealth increases when you do.


One more thing- when discussing pricing, Silviu mentioned you can put a value on ten more years of saved lives- is that in his head for kids or maybe meant for end stage heart patients??



Shorts think they have two and a half months to exit- I reckon less than 6 weeks as the FDA meeting was requested last quarter and Type B meetings get held within 60 days from receipt of the request. Then 30 days for minutes.






Reg- now rocking air pods, should have bought Apple shares